Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glycomimetics Inc (NQ: GLYC )

1.835 -0.005 (-0.27%)
Streaming Delayed Price Updated: 4:15 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 475
Open 1.835
Bid (Size) 1.900 (1)
Ask (Size) 2.460 (118)
Prev. Close 1.840
Today's Range 1.835 - 1.835
52wk Range 1.110 - 3.530
Shares Outstanding 64,450,385
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga

Performance

YTD
-32.54%
-32.54%
1 Month
-34.93%
-34.93%
3 Month
-47.42%
-47.42%
6 Month
+59.57%
+59.57%
1 Year
+31.07%
+31.07%

More News

Read More
GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023
Via InvestorPlace
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
From GlycoMimetics, Inc.
Via Business Wire
Earnings Outlook For GlycoMimetics
Via Benzinga
Earnings Outlook For GlycoMimetics
Via Benzinga
Earnings Scheduled For March 27, 2024
Via Benzinga
GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts
Via Talk Markets
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
From GlycoMimetics, Inc.
Via Business Wire
Why Trinity Place Holdings Shares Are Trading Higher By 80%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
From Apollomics Inc.
Via GlobeNewswire
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
From GlycoMimetics, Inc.
Via Business Wire
Earnings Scheduled For November 3, 2023
Via Benzinga
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
From GlycoMimetics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.